Terms: = Germ cell tumor AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
222 results:
1. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
2. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y; Ueno T; Kojima S; Ikeuchi H; Kitada R; Koyama T; Takahashi F; Takahashi K; Ichimura K; Yoshida A; Sugino H; Mano H; Narita Y; Takahashi M; Kohsaka S
J Neurooncol; 2024 Mar; 167(1):75-88. PubMed ID: 38363490
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic model for assessing the human glioma cell malignancy grade based on mdm2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
[TBL] [Abstract] [Full Text] [Related]
4. Delivery versus Potency in Treating Brain tumors: BI-907828, a mdm2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma.
Zhang W; Vaubel RA; Oh JH; Mladek AC; Talele S; Zhang W; Waller KL; Burgenske DM; Sarkaria JN; Elmquist WF
Mol Cancer Ther; 2024 Jan; 23(1):47-55. PubMed ID: 37828724
[TBL] [Abstract] [Full Text] [Related]
5. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Le Clorennec C; Lee K; Huo Y; Zage PE
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
[TBL] [Abstract] [Full Text] [Related]
6. A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
Miranda J; Vázquez-Blomquist D; Bringas R; Fernandez-de-Cossio J; Palenzuela D; Novoa LI; Bello-Rivero I
BMC Cancer; 2023 Aug; 23(1):806. PubMed ID: 37644431
[TBL] [Abstract] [Full Text] [Related]
7. P53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.
Mehdizadeh R; Madjid Ansari A; Forouzesh F; Shahriari F; Shariatpanahi SP; Salaritabar A; Javidi MA
Sci Rep; 2023 Jul; 13(1):10845. PubMed ID: 37407632
[TBL] [Abstract] [Full Text] [Related]
8. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
9. Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.
Panovska D; Nazari P; Cole B; Creemers PJ; Derweduwe M; Solie L; Van Gassen S; Claeys A; Verbeke T; Cohen EF; Tolstorukov MY; Saeys Y; Van der Planken D; Bosisio FM; Put E; Bamps S; Clement PM; Verfaillie M; Sciot R; Ligon KL; De Vleeschouwer S; Antoranz A; De Smet F
Cell Mol Life Sci; 2023 May; 80(6):147. PubMed ID: 37171617
[TBL] [Abstract] [Full Text] [Related]
10. Structure-based discovery of novel α-aminoketone derivatives as dual p53-mdm2/MDMX inhibitors for the treatment of cancer.
Luo HJ; Si DJ; Sun XJ; Wang MY; Yang YB; Wang B; Wen HM; Li W; Liu J
Eur J Med Chem; 2023 Apr; 252():115282. PubMed ID: 36989812
[TBL] [Abstract] [Full Text] [Related]
11. The mdm2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
[TBL] [Abstract] [Full Text] [Related]
12. EXPRESSION OF GENES INVOLVED IN P53 PATHWAY REGULATION IN NEUROBLASTOMA: A SHORT REVIEW.
Inomistova M; Klymniuk H; Khranovska N; Pavlyk S; Shaida E; Gorbach A; Skachkova O; Shymon D
Exp Oncol; 2022 Dec; 44(4):266-271. PubMed ID: 36811541
[TBL] [Abstract] [Full Text] [Related]
13. mdm2 promotes cancer cell survival through regulating the expression of HIF-1α and pVHL in retinoblastoma.
Zhang S; Xu H; Li W; Ji J; Jin Q; Chen L; Gan Q; Tao Q; Chai Y
Pathol Oncol Res; 2023; 29():1610801. PubMed ID: 36741966
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
[TBL] [Abstract] [Full Text] [Related]
15. cell state-directed therapy - epigenetic modulation of gene transcription demonstrated with a quantitative systems pharmacology model of temozolomide.
Saini A; Ballesta A; Gallo JM
CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):360-374. PubMed ID: 36642831
[TBL] [Abstract] [Full Text] [Related]
16. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract] [Full Text] [Related]
17. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
[TBL] [Abstract] [Full Text] [Related]
18. BI-907828, a novel potent mdm2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract] [Full Text] [Related]
19. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract] [Full Text] [Related]
20. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells
Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L
Front Immunol; 2022; 13():886319. PubMed ID: 35967339
[TBL] [Abstract] [Full Text] [Related]
[Next]
